SLC19A2

Across TCGA pan-cancer cohorts, SLC19A2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC19A2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher SLC19A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC19A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SARC, LUSC, and BLCA are the cancer types where SLC19A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.094	0.632	<.001	6	view →
LUSC	OS	Median	All	0.081	0.818	<.001	6	view →
BLCA	DFS	Median	IV	0.064	0.476	<.001	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.488	.045	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC19A2–SARC (DFS)

Open the SARC breakdown →